Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company focused on developing innovative therapies for ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), with a market capitalization of $1.72 billion, is a biopharmaceutical company focused on developing innovative therapies for challenging diseases, with its ...

Treating CIU with levocetirizine is dominant over placebo, i.e. it increases the number of pruritus-free days and leads to cost savings for society.

Furthermore, other pharmaceutical companies are developing novel treatments for urticaria, which could fragment the market ... atopic dermatitis, systemic sclerosis, and idiopathic pulmonary fibrosis, ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

A pioneering new treatment promises to tackle a wider range of cancers, with fewer side-effects than conventional radiotherapy. It also takes less than a second. In a series of vast underground ...

LOU-064 is under development for the treatment of chronic spontaneous urticaria, chronic idiopathic urticaria, atopic diathesis, hidradenitis suppurativa, relapsing multiple sclerosis (RMS), relapsing ...

Treatment for sleep apnea aims to improve your breathing during sleep and reduce the risk of underlying health concerns. Common options include CPAP machines, oral devices, and lifestyle measures ...

Chronic urticaria occurs in about 0.1% of the population (Greaves, 2000). Patients previously classified as having chronic idiopathic or "ordinary" urticaria are now divided into two groups ...